Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study In Patients With Advanced Pancreatic Cancer At The ESMO Asia Congress 2024
Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study In Patients With Advanced Pancreatic Cancer At The ESMO Asia Congress 2024 . (MENAFN - PR Newswire) 
  
  
 
 
 
 
 
 SAN FRANCISCO and SUZHOU, China, Dec. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108969165/Innovent-Presents-Updated-Data-From-Innovative-Anti-CLDN182-ADC-IBI343-Phase-1-Study-In-Patients-With-Advanced-Pancreatic-Cancer-At-The-ESMO-Asia-Congress-2024
2024-12-08
rss
(MENAFN - PR Newswire) 
  
  
 
 
 
 
 
 SAN FRANCISCO and SUZHOU, China, Dec. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company ...
Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study In Patients With Advanced Pancreatic Cancer At The ESMO Asia Congress 2024